loading
Briacell Therapeutics Corp stock is traded at $0.6345, with a volume of 2.89M. It is down -18.44% in the last 24 hours and down -78.20% over the past month. BriaCell Therapeutics Corp is a clinical-stage immuno-oncology company. The group is developing an entirely new class of targeted immunotherapies to transform cancer care. Its product candidate Bria-IMT, is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer (MBC is breast cancer that has spread to other tissues). Bria-IMT is a targeted cell-based immunotherapy. The company is engaged in developing a Bria-OTS platform of personalized off-the-shelf cell-based immunotherapies. It is being evaluated in a Phase 1/2 clinical study and the treatment is initially focused on patients with breast cancer with an extension to prostate cancer, and other cancers.
See More
Previous Close:
$0.7778
Open:
$0.7102
24h Volume:
2.89M
Relative Volume:
2.51
Market Cap:
$11.13M
Revenue:
-
Net Income/Loss:
$-16.60M
P/E Ratio:
-0.7129
EPS:
-0.89
Net Cash Flow:
$-23.48M
1W Performance:
-21.00%
1M Performance:
-78.20%
6M Performance:
-84.34%
1Y Performance:
-93.07%
1-Day Range:
Value
$0.61
$0.7444
1-Week Range:
Value
$0.61
$0.8099
52-Week Range:
Value
$0.61
$29.40

Briacell Therapeutics Corp Stock (BCTX) Company Profile

Name
Name
Briacell Therapeutics Corp
Name
Phone
(604) 921-1810
Name
Address
3RD FLOOR, BELLEVUE CENTRE, 235-15TH STR, WEST VANCOUVER
Name
Employee
12
Name
Twitter
Name
Next Earnings Date
2024-10-28
Name
Latest SEC Filings
Name
BCTX's Discussions on Twitter

Compare BCTX with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
BCTX
Briacell Therapeutics Corp
0.6343 13.65M 0 -16.60M -23.48M -0.89
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
384.16 96.11B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
552.99 60.40B 14.21B 4.46B 3.56B 39.68
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
423.06 54.91B 2.46B -319.09M -52.09M -2.47
Biotechnology icon
ARGX
Argen X Se Adr
671.58 41.30B 3.05B 1.28B -614.78M 19.58
Biotechnology icon
ONC
Beone Medicines Ltd Adr
297.30 33.25B 3.81B -644.79M -669.77M -6.24

Briacell Therapeutics Corp Stock (BCTX) Upgrades & Downgrades

Date Action Analyst Rating Change
Feb-14-22 Initiated H.C. Wainwright Buy

Briacell Therapeutics Corp Stock (BCTX) Latest News

pulisher
Aug 05, 2025

BriaCell Announces Share Consolidation to Maintain Nasdaq Compliance - TipRanks

Aug 05, 2025
pulisher
Aug 05, 2025

BriaCell Sets August 25 for Major 10:1 Share Consolidation: What Shareholders Must Know - Stock Titan

Aug 05, 2025
pulisher
Aug 05, 2025

BriaCell Announces Proposed Effective Date of Share Consolidation - GlobeNewswire

Aug 05, 2025
pulisher
Aug 05, 2025

My Honest Opinion of Energy Transfer Stock - The Globe and Mail

Aug 05, 2025
pulisher
Aug 05, 2025

Simon Property Reports Strong Q2 2025 Financial Results - The Globe and Mail

Aug 05, 2025
pulisher
Aug 03, 2025

What institutional investors are buying BriaCell Therapeutics Corp. Equity Warrant stockUnlock powerful stock screening techniques - Jammu Links News

Aug 03, 2025
pulisher
Aug 03, 2025

How does BriaCell Therapeutics Corp. compare to its industry peersDiscover high-impact investment opportunities - Jammu Links News

Aug 03, 2025
pulisher
Aug 03, 2025

How does BriaCell Therapeutics Corp. Equity Warrant generate profit in a changing economySuperior risk-adjusted returns - Jammu Links News

Aug 03, 2025
pulisher
Aug 03, 2025

(BCT) Technical Pivots with Risk Controls (BCT:CA) - news.stocktradersdaily.com

Aug 03, 2025
pulisher
Aug 03, 2025

What institutional investors are buying BriaCell Therapeutics Corp. stockDiscover the next big stock winners - Jammu Links News

Aug 03, 2025
pulisher
Aug 03, 2025

What makes BriaCell Therapeutics Corp. stock price move sharplyCapitalize on emerging trends for profits - Jammu Links News

Aug 03, 2025
pulisher
Aug 03, 2025

How volatile is BriaCell Therapeutics Corp. Equity Warrant stock compared to the marketMassive portfolio appreciation - Jammu Links News

Aug 03, 2025
pulisher
Aug 03, 2025

BriaCell Therapeutics Corp. Equity Warrant Stock Analysis and ForecastGet daily updates on promising stocks - Jammu Links News

Aug 03, 2025
pulisher
Aug 03, 2025

How does BriaCell Therapeutics Corp. Equity Warrant compare to its industry peersHigh-octane gains - Jammu Links News

Aug 03, 2025
pulisher
Aug 03, 2025

What makes BriaCell Therapeutics Corp. Equity Warrant stock price move sharplyUnlock powerful market insights for success - Jammu Links News

Aug 03, 2025
pulisher
Aug 03, 2025

What drives BriaCell Therapeutics Corp. Equity Warrant stock priceMaximize returns with data-driven strategies - Jammu Links News

Aug 03, 2025
pulisher
Aug 03, 2025

What is the dividend policy of BriaCell Therapeutics Corp. Equity Warrant stockMaximize gains with expert analysis - Jammu Links News

Aug 03, 2025
pulisher
Aug 03, 2025

Published on: 2025-08-03 12:02:14 - Jammu Links News

Aug 03, 2025
pulisher
Aug 03, 2025

What is the risk reward ratio of investing in BriaCell Therapeutics Corp. Equity Warrant stockAchieve consistent double-digit returns - Jammu Links News

Aug 03, 2025
pulisher
Aug 02, 2025

Should I hold or sell BriaCell Therapeutics Corp. Equity Warrant stock in 2025Tremendous return rates - Jammu Links News

Aug 02, 2025
pulisher
Aug 02, 2025

What catalysts could drive BriaCell Therapeutics Corp. Equity Warrant stock higher in 2025Invest smarter with comprehensive market analysis - Jammu Links News

Aug 02, 2025
pulisher
Aug 02, 2025

How does BriaCell Therapeutics Corp. generate profit in a changing economyProven strategies for superior portfolio growth - Jammu Links News

Aug 02, 2025
pulisher
Aug 02, 2025

What catalysts could drive BriaCell Therapeutics Corp. stock higher in 2025Sky-high return potential - Jammu Links News

Aug 02, 2025
pulisher
Aug 02, 2025

Is BriaCell Therapeutics Corp. Equity Warrant stock overvalued or undervaluedRapid portfolio appreciation - Jammu Links News

Aug 02, 2025
pulisher
Aug 02, 2025

Is it the right time to buy BriaCell Therapeutics Corp. Equity Warrant stockDouble-digit growth - Jammu Links News

Aug 02, 2025
pulisher
Aug 02, 2025

Off-market insider buying at Atico Mining (ATY) - The Globe and Mail

Aug 02, 2025
pulisher
Aug 01, 2025

BriaCell Therapeutics Corp. Recovery Hinges on Volume BreakoutWeekly Setup With 3x Return Potential Published - metal.it

Aug 01, 2025
pulisher
Aug 01, 2025

Is BriaCell Therapeutics Corp. a growth stock or a value stockPre Market Review For Consistent Profits - Jammu Links News

Aug 01, 2025
pulisher
Jul 31, 2025

BriaCell Expands Phase 3 Breast Cancer Study with UCLA Health Partnership - TipRanks

Jul 31, 2025
pulisher
Jul 31, 2025

UCLA Health joins BriaCell’s phase 3 breast cancer study By Investing.com - Investing.com Nigeria

Jul 31, 2025
pulisher
Jul 31, 2025

UCLA Health joins BriaCell’s phase 3 breast cancer study - Investing.com

Jul 31, 2025
pulisher
Jul 31, 2025

BriaCell Adds UCLA Health as Key Site in Pivotal Phase 3 Breast Cancer Study - GlobeNewswire

Jul 31, 2025
pulisher
Jul 31, 2025

FDA Fast-Tracked: UCLA Health to Test BriaCell's Novel Breast Cancer Immunotherapy in Pivotal Phase 3 Trial - Stock Titan

Jul 31, 2025
pulisher
Jul 31, 2025

Foraco International reports Q2 2025 - The Globe and Mail

Jul 31, 2025
pulisher
Jul 30, 2025

WALSH PURE SPREADER -Pure Hedge Division - The Globe and Mail

Jul 30, 2025
pulisher
Jul 30, 2025

BriaCell granted New Zealand patent for cancer immunotherapy method By Investing.com - Investing.com South Africa

Jul 30, 2025
pulisher
Jul 30, 2025

BriaCell granted New Zealand patent for cancer immunotherapy method - Investing.com

Jul 30, 2025
pulisher
Jul 30, 2025

BriaCell Awarded New Zealand Patent for its Whole Cell Technology - GlobeNewswire

Jul 30, 2025
pulisher
Jul 30, 2025

Why BriaCell Therapeutics Corp. Equity Warrant stock attracts strong analyst attentionInvestment Playbook for Growing Markets Shared - metal.it

Jul 30, 2025
pulisher
Jul 30, 2025

BriaCell Secures New Zealand Patent for Cancer Immunotherapy - TipRanks

Jul 30, 2025
pulisher
Jul 30, 2025

BriaCell Secures Game-Changing Cancer Immunotherapy Patent: Breakthrough in Personalized Treatment - Stock Titan

Jul 30, 2025
pulisher
Jul 30, 2025

Published on: 2025-07-30 10:30:41 - metal.it

Jul 30, 2025
pulisher
Jul 30, 2025

BriaCell Therapeutics Files Patent for Cancer Treatment Platform - AInvest

Jul 30, 2025
pulisher
Jul 29, 2025

Is BriaCell Therapeutics Corp. Equity Warrant a Top Dividend Stock to Watch in 2025 - metal.it

Jul 29, 2025
pulisher
Jul 29, 2025

BriaCell’s Subsidiary, BriaPro, Files Patent Application for Immuno-Oncology Platform with Novel Multitargeting Agents - GlobeNewswire

Jul 29, 2025
pulisher
Jul 29, 2025

BriaCell Therapeutics Corp. Recovery Linked to Earnings SurpriseDaily Momentum Screener With Alerts Launched - metal.it

Jul 29, 2025
pulisher
Jul 29, 2025

Published on: 2025-07-29 17:12:14 - metal.it

Jul 29, 2025
pulisher
Jul 29, 2025

BriaCell Therapeutics Corp. Equity Warrant Recovers — But Is It SustainableReal Time Trade Opportunity Alerts Monitor Market Surges - metal.it

Jul 29, 2025
pulisher
Jul 29, 2025

BriaCell’s BriaPro Files Patent for Innovative Cancer Treatment Platform - TipRanks

Jul 29, 2025
pulisher
Jul 29, 2025

Revolutionary Cancer Treatment: BriaCell's New Platform Targets 5 Major Cancer Types Simultaneously - Stock Titan

Jul 29, 2025
pulisher
Jul 29, 2025

Why did BCTX report zero EPS for Q3 2023? - AInvest

Jul 29, 2025

Briacell Therapeutics Corp Stock (BCTX) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$77.10
price down icon 0.87%
$37.26
price down icon 1.65%
$110.72
price down icon 0.83%
$28.24
price down icon 3.16%
$109.96
price down icon 1.00%
biotechnology ONC
$296.81
price down icon 3.39%
Cap:     |  Volume (24h):